Relay Therapeutics
RLAY
17.95
-0.79
-4.22%
Relay Therapeutics
US · RLAY
#2273 by market cap
Listed 2020
17.95
-0.79
-4.22%
Live - 5344 symbols - heartbeat 293s ago
· 2026-10-08 07:00
Pre-market
17.84
-0.61%
After-hours
17.95
0.00%
Overnight
17.95
0.00%
- Market cap
- 3.93B
- P/E (TTM)i
- -11.51
- P/Bi
- 4.42
- EPSi
- -1.61
- Div yieldi
- 0.00%
- 52W posi
- 78%
Reader sentiment
Are you bullish or bearish on RLAY?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 38.43, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +53.44% YoY
Margins
- Operating margin
- -1,971.59%
- Net margin
- -1,800.58%
Key ratios & quality
- Altman Z-Scorei
- 38.43
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | -- | 0 | 82.65M | 3.03M | 1.38M | 25.55M | 10.01M | 15.36M |
| Gross profit | -- | -- | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 8.86M | 13.74M | 38.59M | 57.39M | 65.98M | 74.95M | 76.59M | 56.71M |
| Research & development | 41.03M | 70.31M | 99.86M | 172.65M | 246.36M | 330.02M | 319.09M | 261.38M |
| Operating profit | -49.89M | -84.05M | -55.80M | -227.01M | -310.95M | -379.42M | -385.67M | -302.74M |
| Pretax profit | -48.79M | -75.31M | -52.41M | -363.87M | -290.51M | -341.97M | -337.71M | -276.48M |
| Tax | -- | -- | -- | -- | -- | -- | -- | -- |
| Net profit | -48.79M | -75.31M | -52.41M | -363.87M | -290.51M | -341.97M | -337.71M | -276.48M |
| Basic EPS | -1 | -18 | -5 | -4 | -3 | -3 | -2 | -2 |
| Diluted EPS | -0.75 | -17.59 | -5.40 | -3.82 | -2.59 | -2.79 | -2.36 | -1.61 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 7.68M | 677.00K | 0 | 7.00M | 3.00M | 350.00K |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 18.74M | 13.63M | 12.13M | 12.22M | 11.03M | 14.69M |
| Research & development | 73.81M | 63.90M | 68.26M | 55.42M | 70.56M | 76.48M |
| Operating profit | -84.87M | -76.85M | -80.39M | -60.63M | -78.59M | -90.82M |
| Pretax profit | -77.07M | -70.38M | -74.15M | -54.89M | -73.29M | -83.71M |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -77.07M | -70.38M | -74.15M | -54.89M | -73.29M | -83.71M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.46 | -0.41 | -0.43 | -0.32 | -0.41 | -0.41 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 424.10M | 360.54M | 770.10M | 976.24M | 1.02B | 770.10M | 809.20M | 578.28M |
| Cash & ST investments | 421.51M | 355.82M | 678.06M | 958.07M | 998.92M | 750.09M | 781.32M | 554.52M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 428.61M | 393.07M | 799.83M | 1.01B | 1.10B | 843.98M | 871.30M | 621.33M |
| Total current liabilities | 6.87M | 11.99M | 13.63M | 24.32M | 63.71M | 30.27M | 50.73M | 25.58M |
| Short-term debt | 178.00K | 1.25M | 1.52M | 1.84M | 4.28M | 4.96M | 5.73M | 3.77M |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 539,538,000.00 | 573,506,000.00 | 36,536,000.00 | 110,635,000.00 | 149,553,000.00 | 91,977,000.00 | 93,504,000.00 | 54,271,000.00 |
| Total equity | -110.93M | -180.44M | 763.29M | 897.81M | 950.22M | 752.00M | 777.79M | 567.06M |
| Retained earnings | -114.18M | -189.48M | -404.23M | -768.10M | -1.06B | -1.40B | -1.74B | -2.01B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 739.66M | 680.39M | 624.01M | 578.28M | 658.46M | 928.08M |
| Cash & ST investments | 710.36M | 656.78M | 596.43M | 554.52M | 642.07M | 910.93M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 799.36M | 728.84M | 670.00M | 621.33M | 699.61M | 967.46M |
| Total current liabilities | 37.05M | 32.53M | 32.61M | 25.58M | 29.75M | 50.80M |
| Short-term debt | 5.93M | 3.53M | 3.64M | 3.77M | 3.89M | 4.01M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 78,281,000.00 | 63,183,000.00 | 62,291,000.00 | 54,271,000.00 | 57,430,000.00 | 77,448,000.00 |
| Total equity | 721.08M | 665.66M | 607.71M | 567.06M | 642.18M | 890.01M |
| Retained earnings | -1.82B | -1.89B | -1.96B | -2.01B | -2.09B | -2.17B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -44.14M | -66.13M | -102.49M | -74.41M | -229.49M | -300.32M | -249.11M | -235.46M |
| Depreciation & amortization | 2.15M | 2.85M | 3.55M | 3.93M | 4.13M | 5.27M | 5.46M | 3.56M |
| Free cash flow | -45.82M | -74.14M | -104.42M | -77.88M | -238.55M | -304.44M | -251.13M | -235.87M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | 0 | 425.29M | 382.21M | 284.74M | 30.28M | 265.89M | 0 |
| Ending cash balance | 422.38M | 42.83M | 448.52M | 282.70M | 154.37M | 146.44M | 126.41M | 85.35M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -73.21M | -55.26M | -62.12M | -44.87M | -51.11M | -54.11M |
| Depreciation & amortization | 1.21M | 1.00M | 748.00K | 599.00K | 504.00K | 360.00K |
| Free cash flow | -73.59M | -55.29M | -62.12M | -44.87M | -51.11M | -54.11M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 0 | 0 | 0 | 137.09M | 318.94M |
| Ending cash balance | 95.66M | 116.20M | 93.82M | 85.35M | 205.93M | 122.53M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -78.99 | -43.81 | -31.44 | -40.18 | -44.15 | -41.12 |
| ROA %i | -11.38 | -18.33 | -38.60 | -40.25 | -27.56 | -35.19 | -39.38 | -37.05 |
| ROIC %i | -- | -- | -73.91 | -42.69 | -31.04 | -41.14 | -45.65 | -42.57 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- | -47.71 | -40.14 |
| EBIT margin %i | -- | -- | -67.51 | -7,494.45 | -22,516.44 | -1,485.25 | -3,854.04 | -1,971.59 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 61.78 | 30.08 | 56.49 | 40.14 | 16.00 | 25.44 | 15.95 | 22.61 |
| Quick ratioi | 61.40 | 29.69 | 55.80 | 39.60 | 15.76 | 24.78 | 15.40 | 21.68 |
| Debt / assetsi | 0.04 | 6.32 | 3.05 | 2.27 | 5.25 | 6.34 | 5.57 | 5.22 |
| LT debt / equityi | -- | -- | 3.00 | 2.35 | 5.63 | 6.45 | 5.50 | 5.06 |
| Interest coveragei | -- | -- | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -32.39 | 48.94 | 123.20 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -45.46 | -46.24 | -41.14 | -41.12 | -40.01 | -36.77 |
| ROA %i | -40.64 | -41.50 | -37.20 | -37.05 | -36.39 | -33.72 |
| ROIC %i | -46.86 | -47.98 | -42.87 | -42.57 | -41.23 | -38.34 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -4,927.05 | -4,106.10 | -3,914.87 | -1,971.59 | -2,776.87 | -2,999.37 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 19.96 | 20.92 | 19.14 | 22.61 | 22.13 | 18.27 |
| Quick ratioi | 19.17 | 20.19 | 18.29 | 21.68 | 21.58 | 17.93 |
| Debt / assetsi | 5.90 | 4.69 | 4.97 | 5.22 | 4.51 | 3.17 |
| LT debt / equityi | 5.72 | 4.61 | 4.88 | 5.06 | 4.31 | 2.99 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Using innovative experimental and computational approaches on protein motion for making medicines100.00%
Quote time 2026-10-08 07:00:27 · For reference only, not investment advice and not tailored to your situation.